LRCH2

Summary

LRCH2 (leucine rich repeats and calponin homology domain containing 2, HGNC:29292) is a protein-coding gene on chromosome Xq23, encoding Leucine-rich repeat and calponin homology domain-containing protein 2 (Q5VUJ6). May play a role in the organization of the cytoskeleton.

This gene encodes a member of the leucine-rich repeat and calponin homology domain-containing protein family. These family members contain multiple N-terminal leucine-rich repeats, in addition to a C-terminal calponin homology domain, a type of domain that mediates interactions with actin filaments. These proteins are conserved across animal species, and studies of a similar Drosophila protein indicate a function as a cytoskeletal scaffolding protein. Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 57631 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 437 total — 1 pathogenic
• MANE Select transcript: NM_020871

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29292
Approved symbol	LRCH2
Name	leucine rich repeats and calponin homology domain containing 2
Location	Xq23
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1495
Ensembl gene	ENSG00000130224
Ensembl biotype	protein_coding
Entrez	57631

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000317135, ENST00000538422, ENST00000857824

RefSeq mRNA: 2 — MANE Select: NM_020871 NM_001243963, NM_020871

CCDS: CCDS48155, CCDS59175

Canonical transcript exons

ENST00000317135 — 21 exons

Exon	Start	End
ENSE00000893712	115126843	115126893
ENSE00000893717	115150022	115150070
ENSE00000893718	115156602	115156667
ENSE00000893720	115165405	115165463
ENSE00000893721	115165558	115165655
ENSE00000893722	115165841	115165952
ENSE00000893723	115166255	115166342
ENSE00000893724	115170299	115170432
ENSE00001126344	115163676	115163783
ENSE00001126364	115179427	115179563
ENSE00001139020	115149827	115149943
ENSE00001217430	115123945	115124002
ENSE00001217439	115130155	115130199
ENSE00001217444	115122527	115122604
ENSE00001217450	115122760	115122897
ENSE00001217462	115123080	115123192
ENSE00001375363	115184411	115184537
ENSE00001376389	115179646	115179751
ENSE00001456458	115110616	115113335
ENSE00001769531	115188226	115188370
ENSE00003847550	115233693	115234096

Expression profiles

Bgee: expression breadth ubiquitous, 207 present calls, max score 87.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.0058 / max 108.5483, expressed in 978 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200239	3.0251	896
200240	0.9807	520

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	87.40	gold quality
cortical plate	UBERON:0005343	86.00	gold quality
ventricular zone	UBERON:0003053	83.29	gold quality
cardiac muscle of right atrium	UBERON:0003379	81.49	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.29	gold quality
muscle layer of sigmoid colon	UBERON:0035805	79.80	gold quality
calcaneal tendon	UBERON:0003701	78.71	gold quality
tibial artery	UBERON:0007610	78.67	gold quality
popliteal artery	UBERON:0002250	78.65	gold quality
seminal vesicle	UBERON:0000998	78.64	gold quality
epithelial cell of pancreas	CL:0000083	77.88	silver quality
smooth muscle tissue	UBERON:0001135	77.71	gold quality
cauda epididymis	UBERON:0004360	76.96	gold quality
aorta	UBERON:0000947	76.69	gold quality
adrenal tissue	UBERON:0018303	76.39	gold quality
germinal epithelium of ovary	UBERON:0001304	76.37	gold quality
urethra	UBERON:0000057	76.23	gold quality
left ovary	UBERON:0002119	76.02	gold quality
stromal cell of endometrium	CL:0002255	75.92	gold quality
ovary	UBERON:0000992	75.80	gold quality
lower lobe of lung	UBERON:0008949	75.67	gold quality
myometrium	UBERON:0001296	75.33	gold quality
prostate gland	UBERON:0002367	75.32	gold quality
right ovary	UBERON:0002118	75.23	gold quality
urinary bladder	UBERON:0001255	74.91	gold quality
visceral pleura	UBERON:0002401	74.91	gold quality
mucosa of stomach	UBERON:0001199	74.84	gold quality
body of uterus	UBERON:0009853	74.82	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	74.67	gold quality
descending thoracic aorta	UBERON:0002345	74.57	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-81608	yes	4.81
E-ANND-3	no	4.60
E-ENAD-27	no	3.48

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

148 targeting LRCH2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lrch2	ENSDARG00000075580
mus_musculus	Lrch2	ENSMUSG00000031290
rattus_norvegicus	Lrch2	ENSRNOG00000029582

Paralogs (31): LRRC7 (ENSG00000033122), PHLPP2 (ENSG00000040199), LRRC40 (ENSG00000066557), LRCH4 (ENSG00000077454), PHLPP1 (ENSG00000081913), SHOC2 (ENSG00000108061), ERBIN (ENSG00000112851), LRRC39 (ENSG00000122477), LRCH1 (ENSG00000136141), LRRC8A (ENSG00000136802), LRRC1 (ENSG00000137269), MFHAS1 (ENSG00000147324), LRRC27 (ENSG00000148814), LRRK1 (ENSG00000154237), LRRC58 (ENSG00000163428), LRRC2 (ENSG00000163827), LRRC18 (ENSG00000165383), LRRC28 (ENSG00000168904), LRRC8E (ENSG00000171017), LRRC8C (ENSG00000171488), LRRC8D (ENSG00000171492), PIDD1 (ENSG00000177595), SCRIB (ENSG00000180900), LRCH3 (ENSG00000186001), LRRIQ4 (ENSG00000188306), LRRC8B (ENSG00000197147), LRRC10 (ENSG00000198812), LRRC10B (ENSG00000204950), LRRC30 (ENSG00000206422), LRRC69 (ENSG00000214954), LRRD1 (ENSG00000240720)

Protein

Protein identifiers

Leucine-rich repeat and calponin homology domain-containing protein 2 — Q5VUJ6 (reviewed: Q5VUJ6)

All UniProt accessions (1): Q5VUJ6

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the organization of the cytoskeleton.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5VUJ6-1	1	yes
Q5VUJ6-2	2

RefSeq proteins (2): NP_001230892, NP_065922* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR001715	CH_dom	Domain
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR036872	CH_dom_sf	Homologous_superfamily
IPR050216	LRR_domain-containing	Family

Pfam: PF00307, PF13855

UniProt features (23 total): repeat 9, region of interest 5, compositionally biased region 4, chain 1, domain 1, coiled-coil region 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VUJ6-F1	62.83	0.24

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 127 (showing top): RRAGTTGT_UNKNOWN, TAATAAT_MIR126, BENPORATH_ES_WITH_H3K27ME3, TGCACTT_MIR519C_MIR519B_MIR519A, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, BEIER_GLIOMA_STEM_CELL_DN, ATGTTAA_MIR302C, AACWWCAANK_UNKNOWN, AGTCTTA_MIR499, KOYAMA_SEMA3B_TARGETS_UP, GATA6_01, ATTCTTT_MIR186, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

1108 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRCH2	LHFPL1	Q86WI0	580
LRCH2	TTC32	Q5I0X7	451
LRCH2	HTR2C	P28335	443
LRCH2	AMOT	Q4VCS5	406
LRCH2	ERICH6	Q7L0X2	391
LRCH2	HAUS3	Q68CZ6	386
LRCH2	ZDHHC23	Q8IYP9	375
LRCH2	OR2AE1	Q8NHA4	374
LRCH2	CTCF	P49711	373
LRCH2	ATRX	P46100	366
LRCH2	CFAP95	Q5VTT2	349
LRCH2	EML3	Q32P44	331
LRCH2	ZSWIM4	Q9H7M6	326
LRCH2	L3HYPDH	Q96EM0	324
LRCH2	TBC1D8B	Q0IIM8	322
LRCH2	CSTL1	Q9H114	322

IntAct

85 interactions, top by confidence:

A	B	Type	Score
MOB1B	LATS1	psi-mi:“MI:0914”(association)	0.840
DOCK8	LRCH2	psi-mi:“MI:0915”(physical association)	0.740
DOCK8	LRCH2	psi-mi:“MI:0914”(association)	0.740
MOB1A	LATS1	psi-mi:“MI:0914”(association)	0.670
ARPC3	ARPC2	psi-mi:“MI:0914”(association)	0.640
RCCD1	SPAG9	psi-mi:“MI:0914”(association)	0.640
DOCK8	LRCH4	psi-mi:“MI:0914”(association)	0.620
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
BPNT1	GTPBP10	psi-mi:“MI:0914”(association)	0.530
SKP2	DPYSL4	psi-mi:“MI:0914”(association)	0.530
NPRL2	ZBTB5	psi-mi:“MI:0914”(association)	0.530
PSME1	POLR3A	psi-mi:“MI:0914”(association)	0.530
TGM4	DDHD2	psi-mi:“MI:0914”(association)	0.530
LRCH3	LRCH2	psi-mi:“MI:0914”(association)	0.530
DOCK7	LRCH2	psi-mi:“MI:0914”(association)	0.530
CBY1	CFAP410	psi-mi:“MI:0914”(association)	0.510
DCAF7	CLASP2	psi-mi:“MI:0914”(association)	0.510
MOB1B	PPP6C	psi-mi:“MI:2364”(proximity)	0.480
MOB1A	ANKRD28	psi-mi:“MI:0914”(association)	0.420

BioGRID (105): LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS), CBY1 (Affinity Capture-MS), LRCH2 (Affinity Capture-MS)

ESM2 similar proteins: A1A4L4, A1A5R8, A2RRS8, A5PLL1, B0BF33, D4A039, D4AEC2, P0C6C1, Q08AD1, Q08AX9, Q0P557, Q0VA42, Q12923, Q13009, Q3B7T8, Q3UMB5, Q3UMG5, Q3UQI9, Q3UUF8, Q4R9E9, Q5JTW2, Q5PQ89, Q5SUS0, Q5TB30, Q5VUJ6, Q5ZIX8, Q64512, Q68FF0, Q6AY22, Q6GQJ2, Q6IE81, Q6IE82, Q6ING4, Q6IRU7, Q6NPP4, Q6NSI8, Q6P1H6, Q6ZPI0, Q7TP65, Q7ZVP1

Diamond homologs: O75427, P26932, P41737, P52735, P62046, Q3UMG5, Q5S006, Q5VUJ6, Q60992, Q6Z8P4, Q8BVU0, Q921G6, Q96II8, Q9R0C8, Q9Y2L9, B9EUM5, B9G8P1, O14188, P14318, P15498, P19966, P27870, P31232, P37397, P37802, P37803, P37804, P37805, P51911, P54100, Q01995, Q08091, Q08092, Q08093, Q08094, Q08290, Q08DN7, Q14155, Q15052, Q15417

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

437 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	321
Likely benign	30
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1342852	NM_020871.4(LRCH2):c.772A>G (p.Lys258Glu)	Pathogenic

SpliceAI

3323 predictions. Top by Δscore:

Variant	Effect	Δscore
X:115122759:CCA:C	donor_gain	1.0000
X:115123074:A:AC	donor_gain	1.0000
X:115123074:ACTT:A	donor_loss	1.0000
X:115123075:C:CC	donor_gain	1.0000
X:115123076:TTAC:T	donor_loss	1.0000
X:115123078:A:AC	donor_gain	1.0000
X:115123078:ACGTT:A	donor_loss	1.0000
X:115123079:C:CG	donor_gain	1.0000
X:115123079:CG:C	donor_gain	1.0000
X:115123079:CGT:C	donor_gain	1.0000
X:115123079:CGTT:C	donor_gain	1.0000
X:115123079:CGTTG:C	donor_gain	1.0000
X:115123188:AAAAG:A	acceptor_gain	1.0000
X:115123189:AAAG:A	acceptor_gain	1.0000
X:115123190:AAG:A	acceptor_gain	1.0000
X:115123191:AG:A	acceptor_gain	1.0000
X:115123193:C:CC	acceptor_gain	1.0000
X:115123194:T:C	acceptor_loss	1.0000
X:115123998:TATTC:T	acceptor_gain	1.0000
X:115124000:TTC:T	acceptor_gain	1.0000
X:115124000:TTCC:T	acceptor_loss	1.0000
X:115124002:CCTA:C	acceptor_loss	1.0000
X:115124003:C:A	acceptor_loss	1.0000
X:115126901:A:C	acceptor_gain	1.0000
X:115150069:CA:C	acceptor_gain	1.0000
X:115150071:C:CC	acceptor_gain	1.0000
X:115158347:T:C	acceptor_gain	1.0000
X:115158347:T:TC	acceptor_gain	1.0000
X:115163670:GAATA:G	donor_loss	1.0000
X:115163674:ACCTG:A	donor_loss	1.0000

AlphaMissense

5015 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:115113262:A:G	L751P	1.000
X:115113262:A:T	L751H	1.000
X:115113271:A:T	V748D	1.000
X:115113274:G:T	T747K	1.000
X:115113310:A:C	I735S	1.000
X:115113310:A:G	I735T	1.000
X:115113310:A:T	I735N	1.000
X:115113324:A:C	C730W	1.000
X:115113325:C:T	C730Y	1.000
X:115113326:A:G	C730R	1.000
X:115122534:A:T	V724D	1.000
X:115122548:A:C	C719W	1.000
X:115122549:C:T	C719Y	1.000
X:115122550:A:G	C719R	1.000
X:115122552:G:T	A718D	1.000
X:115122553:C:G	A718P	1.000
X:115122558:A:G	L716P	1.000
X:115122560:A:C	F715L	1.000
X:115122560:A:T	F715L	1.000
X:115122561:A:C	F715C	1.000
X:115122561:A:G	F715S	1.000
X:115122562:A:G	F715L	1.000
X:115122570:A:T	V712E	1.000
X:115122572:A:C	N711K	1.000
X:115122572:A:T	N711K	1.000
X:115122573:T:A	N711I	1.000
X:115122573:T:C	N711S	1.000
X:115122573:T:G	N711T	1.000
X:115122574:T:A	N711Y	1.000
X:115122574:T:C	N711D	1.000

dbSNP variants (sampled 300 via entrez): RS1000113932 (X:115116945 T>A), RS1000164860 (X:115159881 A>G), RS1000193794 (X:115174504 T>C), RS1000274183 (X:115174261 G>A,C), RS1000287337 (X:115231626 T>C), RS1000315509 (X:115196885 G>A), RS1000397031 (X:115165164 T>C), RS1000400726 (X:115117525 A>C), RS1000403754 (X:115183968 A>G), RS1000495313 (X:115203909 C>A), RS1000515291 (X:115213382 A>T), RS1000581303 (X:115154671 G>A,T), RS1000636189 (X:115232177 T>C), RS1000640807 (X:115135286 A>G), RS1000753984 (X:115145295 T>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:148840

GenCC curated gene-disease

Mondo (4): cerebellar ataxia (MONDO:0000437), demyelinating polyneuropathy (MONDO:0003334), Kleine-Levin syndrome (MONDO:0007863), neurodevelopmental disorder (MONDO:0700092)

Orphanet (2): Rare ataxia (Orphanet:102002), Kleine-Levin syndrome (Orphanet:33543)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D002524	Cerebellar Ataxia	C10.228.140.252.190; C10.597.350.090.500; C23.888.592.350.090.200
D017593	Kleine-Levin Syndrome	C10.886.425.800.200.500; F03.870.400.800.200.500
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression	4
Aflatoxin B1	affects expression, decreases methylation	2
bisphenol F	increases methylation	1
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
bisphenol A	increases methylation	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	increases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	increases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation, affects cotreatment	1
Temozolomide	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Air Pollutants	decreases expression, increases abundance	1
Ethanol	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Doxorubicin	decreases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Silicon Dioxide	increases expression	1
Cyclosporine	increases expression	1
Antirheumatic Agents	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00950196	PHASE4	COMPLETED	Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
NCT04107740	PHASE4	COMPLETED	C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT01970098	PHASE3	COMPLETED	A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970111	PHASE3	COMPLETED	An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970124	PHASE3	COMPLETED	A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970137	PHASE3	COMPLETED	A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT02889302	PHASE3	COMPLETED	An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT03408080	PHASE3	ACTIVE_NOT_RECRUITING	Open Pilot Trial of BHV-4157
NCT03701399	PHASE3	ACTIVE_NOT_RECRUITING	Troriluzole in Adult Participants With Spinocerebellar Ataxia
NCT03901638	PHASE3	TERMINATED	Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
NCT07040137	PHASE3	RECRUITING	Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
NCT01349270	PHASE3	COMPLETED	Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT00034242	PHASE2	COMPLETED	High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
NCT00202397	PHASE2	COMPLETED	Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
NCT00863538	PHASE2	COMPLETED	Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01004016	PHASE2	COMPLETED	A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01350440	PHASE2	COMPLETED	Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
NCT02540655	PHASE2	COMPLETED	Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia
NCT03932669	PHASE2	COMPLETED	Effect of Nilotinib in Cerebellar Ataxia Patients
NCT04301284	PHASE2	WITHDRAWN	Study of CAD-1883 for Spinocerebellar Ataxia
NCT05125666	PHASE2	UNKNOWN	Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection
NCT06397274	PHASE2	NOT_YET_RECRUITING	Stemchymal® for Polyglutamine Spinocerebellar Ataxia
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00683943	PHASE1	COMPLETED	Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
NCT02287064	PHASE1	UNKNOWN	An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
NCT05157802	PHASE1	ACTIVE_NOT_RECRUITING	Promoting Physical Activity Engagement for People With Early-stage Cerebellar Ataxia
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01104649	PHASE2/PHASE3	COMPLETED	Efficacy of Riluzole in Hereditary Cerebellar Ataxia
NCT02960893	PHASE2/PHASE3	COMPLETED	Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
NCT00244361	PHASE1/PHASE2	COMPLETED	Effectiveness of Rituximab in Pediatric OMS Patients.